بدائل البحث:
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), linear decrease (توسيع البحث)
largest decrease » marked decrease (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
clinical decrease » clinical disease (توسيع البحث), clinical case (توسيع البحث), linear decrease (توسيع البحث)
largest decrease » marked decrease (توسيع البحث)
larger decrease » marked decrease (توسيع البحث)
-
2001
Presentation 3_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
منشور في 2025"…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …"
-
2002
Data Sheet 1_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
منشور في 2025"…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …"
-
2003
Data Sheet 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhibi...
منشور في 2025"…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …"
-
2004
Presentation 2_A phase 2a double-blind, placebo-controlled, randomized clinical trial evaluating the efficacy and safety of NuGel, a novel topical GPCR19-mediated inflammasome inhi...
منشور في 2025"…</p>Results<p>NuGel (0.3% [Nu0.3] and 0.5% [Nu0.5]) was well-tolerated, with no adverse drug reactions or serious adverse events. Nu0.3 showed a significant decrease in EASI score from baseline (-12.2%, [-30.3%, 5.9%], p = 0.04). …"
-
2005
-
2006
-
2007
Schematic flowchart of the study.
منشور في 2025"…Factors such as individuals’ age (p = 0.029), underlying comorbid conditions (30.3%; p = 0.035), and longer employment duration (28%; p = 0.034) were significantly associated with IGRA positivity. Further, IGRA positivity was significantly associated with decreased RDW standard deviation (RDW-SD). …"
-
2008
Comorbidities among LTBI-positive individuals.
منشور في 2025"…Factors such as individuals’ age (p = 0.029), underlying comorbid conditions (30.3%; p = 0.035), and longer employment duration (28%; p = 0.034) were significantly associated with IGRA positivity. Further, IGRA positivity was significantly associated with decreased RDW standard deviation (RDW-SD). …"
-
2009
-
2010
Summary of correlations in previous studies.
منشور في 2025"…During this period, the number of weekly new cases exhibited a similar trend, and the results indicated a significant correlation between the viral concentration and the number of weekly new cases (spearman’s r = 0.93, P < 0.001). …"
-
2011
The characteristics of nine WWTPs.
منشور في 2025"…During this period, the number of weekly new cases exhibited a similar trend, and the results indicated a significant correlation between the viral concentration and the number of weekly new cases (spearman’s r = 0.93, P < 0.001). …"
-
2012
Variables name and variable measurement.
منشور في 2025"…</p><p>Results</p><p>In the first period of DRG reform, total hospital costs decreased by 1.23% per month (95% CI, 0.88%-1.59%), patient cost-sharing decreased by 1.46% per month (95% CI, 1.09%-1.83%), patient sharing ratio decreased by 0.23% per month (95% CI, 0.06%-0.40%), and length of stay decreased by 0.56% per month (95% CI, 0.27%-0.84%). …"
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020